ES2493440T3 - Desacilación de LPS en bacterias Gram negativas - Google Patents

Desacilación de LPS en bacterias Gram negativas Download PDF

Info

Publication number
ES2493440T3
ES2493440T3 ES05815467.5T ES05815467T ES2493440T3 ES 2493440 T3 ES2493440 T3 ES 2493440T3 ES 05815467 T ES05815467 T ES 05815467T ES 2493440 T3 ES2493440 T3 ES 2493440T3
Authority
ES
Spain
Prior art keywords
lps
pagl
lipid
bacteria
pertussis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05815467.5T
Other languages
English (en)
Spanish (es)
Inventor
Johannes Petrus Maria Tommassen
Peter André VAN DER LEY
Jeroen Johannes Gerardus Geurtsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STAAT DER NEDERLANDEN VERT DOOR DE MINISTER VAN VWS MINISTERIE VAN VOLKSGEZONDHEID WELZIJN EN SPORT
Nederlanden Staat
Original Assignee
STAAT DER NEDERLANDEN VERT DOOR DE MINISTER VAN VWS MINISTERIE VAN VOLKSGEZONDHEID WELZIJN EN SPORT
Nederlanden Staat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by STAAT DER NEDERLANDEN VERT DOOR DE MINISTER VAN VWS MINISTERIE VAN VOLKSGEZONDHEID WELZIJN EN SPORT, Nederlanden Staat filed Critical STAAT DER NEDERLANDEN VERT DOOR DE MINISTER VAN VWS MINISTERIE VAN VOLKSGEZONDHEID WELZIJN EN SPORT
Application granted granted Critical
Publication of ES2493440T3 publication Critical patent/ES2493440T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/18—Carboxylic ester hydrolases (3.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ES05815467.5T 2004-12-17 2005-12-16 Desacilación de LPS en bacterias Gram negativas Expired - Lifetime ES2493440T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04078445 2004-12-17
EP04078445 2004-12-17
PCT/NL2005/050081 WO2006065139A2 (en) 2004-12-17 2005-12-16 Deacylation of lps in gram negative bacteria

Publications (1)

Publication Number Publication Date
ES2493440T3 true ES2493440T3 (es) 2014-09-11

Family

ID=34928754

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05815467.5T Expired - Lifetime ES2493440T3 (es) 2004-12-17 2005-12-16 Desacilación de LPS en bacterias Gram negativas

Country Status (15)

Country Link
US (1) US8048433B2 (enExample)
EP (1) EP1828378B1 (enExample)
JP (1) JP5378685B2 (enExample)
CN (1) CN101203605B (enExample)
AU (1) AU2005317304B2 (enExample)
BR (1) BRPI0519923A8 (enExample)
CA (1) CA2590906C (enExample)
DK (1) DK1828378T3 (enExample)
ES (1) ES2493440T3 (enExample)
MX (1) MX2007007288A (enExample)
NO (1) NO340331B1 (enExample)
NZ (1) NZ555889A (enExample)
PL (1) PL1828378T3 (enExample)
PT (1) PT1828378E (enExample)
WO (1) WO2006065139A2 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2134743E (pt) * 2007-03-26 2012-12-21 Nederlanden Staat Vacinas melhoradas contra bordotella pertussis baseadas nos mutantes do lps glicosiltransferase
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
EA031879B1 (ru) 2013-06-04 2019-03-29 Пётр Геннадиевич Апарин Модифицированный липополисахарид эндотоксичных бактерий (варианты), комбинация модифицированных липополисахаридов (варианты) и включающие их вакцина (варианты) и фармацевтическая композиция (варианты)
US11052142B2 (en) 2013-06-04 2021-07-06 Petr G. Aparin Modified endotoxic bacteria lipopolysaccharide (variants), combination of modified lipopolysaccharides (variants) and, containing same, a vaccine (variants) and a pharmaceutical composition (variants)
US20160193322A1 (en) 2013-08-05 2016-07-07 Glaxosmithkline Biologicals S.A. Combination immunogenic compositions
WO2015179270A2 (en) 2014-05-19 2015-11-26 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
CN104388368B (zh) * 2014-10-30 2017-02-15 四川农业大学 一株低内毒素大肠杆菌原核表达工程菌突变株及构建方法
WO2017129752A1 (en) * 2016-01-28 2017-08-03 De Staat Der Nederlanden, Vert. Door De Minister Van Vws, Ministerie Van Volksgezondheid, Welzijn En Sport Modified tetra-acylated neisserial lps
CN105567620B (zh) * 2016-01-29 2019-03-19 江南大学 一株产减毒类脂A的Cronobacter sakazakii突变株及其应用
CN105695540A (zh) * 2016-03-18 2016-06-22 辽宁成大生物股份有限公司 一种革兰氏阴性菌胞壁抗原的制备方法
CN110461865A (zh) * 2017-03-13 2019-11-15 由卫生福利和体育大臣代表的荷兰王国 包含具有降低的反应原性的lps的博德特氏菌疫苗
WO2018213242A1 (en) * 2017-05-15 2018-11-22 University Of Maryland, Baltimore Live salmonella typhi vectors engineered to express heterologous outer membrane protein antigens and methods of use thereof
KR102822764B1 (ko) * 2017-12-04 2025-06-19 인트라백 비.브이. 외막 소포의 생성을 위한 개선된 방법
US20230183656A1 (en) * 2020-05-14 2023-06-15 Merck Patent Gmbh Methods and compositions for purifying adeno associated virus particles or adenoviruses
WO2022049222A1 (en) 2020-09-04 2022-03-10 Intravacc B.V. Ompa mutations enhance omv production in bordetella pertussis
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH650681A5 (en) * 1981-08-14 1985-08-15 Dso Pharmachim Whooping cough vaccine
JP2918895B2 (ja) * 1987-09-04 1999-07-12 アムジエン・インコーポレーテツド 組換え型ｄｎａ由来ボルデテラ毒素サブユニット類似体
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
ATE263244T1 (de) * 1992-08-18 2004-04-15 Dimminaco Ag Bordetella bronchiseptica impfstoff
CA2220048C (en) * 1995-05-04 2006-03-07 Connaught Laboratories Limited Acellular pertussis vaccines and methods of preparation thereof
US6887483B2 (en) 1995-12-01 2005-05-03 University Of Iowa Research Foundation Non-toxic mutants of pathogenic gram-negative bacteria
ATE278419T1 (de) * 1997-04-01 2004-10-15 Corixa Corp Wässerige immunologische adjuvantzusammensetzungen aus monophosphoryllipid a
CA2264970A1 (en) 1998-03-10 1999-09-10 American Cyanamid Company Antigenic conjugates of conserved lipolysaccharides of gram negative bacteria
US6482807B1 (en) * 1998-11-03 2002-11-19 De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur LPS with reduced toxicity from genetically modified gram negative bacteria
US6531131B1 (en) * 1999-08-10 2003-03-11 The United States Of America As Represented By The Department Of Health And Human Services Conjugate vaccine for Neisseria meningitidis
US20030113742A1 (en) * 2001-04-20 2003-06-19 University Of Iowa Research Foundation Methods and compositions for the modulation of biofilm formation

Also Published As

Publication number Publication date
JP5378685B2 (ja) 2013-12-25
NO340331B1 (no) 2017-04-03
NO20073088L (no) 2007-09-17
BRPI0519923A2 (pt) 2009-08-11
WO2006065139A3 (en) 2006-10-19
US8048433B2 (en) 2011-11-01
DK1828378T3 (da) 2014-09-01
JP2008523805A (ja) 2008-07-10
EP1828378B1 (en) 2014-06-11
CN101203605B (zh) 2016-01-27
PL1828378T3 (pl) 2014-10-31
CA2590906A1 (en) 2006-06-22
NZ555889A (en) 2009-07-31
MX2007007288A (es) 2008-02-25
BRPI0519923A8 (pt) 2018-01-23
AU2005317304B2 (en) 2011-06-23
PT1828378E (pt) 2014-10-10
CN101203605A (zh) 2008-06-18
EP1828378A2 (en) 2007-09-05
AU2005317304A1 (en) 2006-06-22
CA2590906C (en) 2017-01-03
US20080274145A1 (en) 2008-11-06
WO2006065139A2 (en) 2006-06-22

Similar Documents

Publication Publication Date Title
ES2493440T3 (es) Desacilación de LPS en bacterias Gram negativas
Bager et al. Outer membrane vesicles reflect environmental cues in Gallibacterium anatis
AU2012214677B2 (en) Immunogenic composition comprising alpha-hemolysin oligopeptides
US10174085B2 (en) Toxoid peptides derived from phenol soluble modulin, delta toxin, superantigens, and fusions thereof
AU2012345645A1 (en) Immunogenic composition comprising panton-valentine leukocidin (PVL) derived polypeptides
US11421021B2 (en) Immunogenic compositions comprising Staphylococcus aureus leukocidin LukA and LukB derived polypeptides
US20220288183A1 (en) Vaccine constructs and uses thereof against staphylococcus infections
ES2367128T3 (es) Procedimiento para preparar una variante del antígeno protector de superficie de erysipelothrix rhusiopathiae en e. coli.
de Faria Siqueira et al. Immunization with a nontoxic naturally occurring Clostridium perfringens alpha toxin induces neutralizing antibodies in rabbits
CA2378862C (en) Multi-component vaccine to protect against disease caused by haemophilus influenzae and moraxella catarrhalis
US11826412B2 (en) Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
Jurado-Martín et al. Proteomic approach to identify host cell attachment proteins provides protective Pseudomonas aeruginosa vaccine antigen FtsZ
Jang et al. Comparative structural and immunological analysis of outer membrane proteins and dermonecrotic toxin in Bordetella bronchiseptica canine isolate
Traidej Virulence and molecular analysis of Pseudomonas protease IV, a lysine-specific endopeptidase
Yılmaz Assessment of immune protective capacities of the recombinant outer membrane protein Q, iron superoxide dismutase and putative lipoprotein from Bordetella pertussis
Conover An examination of the function and the transcriptional regulation of the Bps polysaccharide in Bordetella pertussis pathogenesis and biofilm development
Fulcher Effectors of Haemophilus ducreyi pathogenesis